Stem cell frequency at diagnosis offers a new prognostic factor in AML, and a large CD34+CD38- population reflects a higher percentage of chemotherapy-resistant cells that will lead to the outgrowth of minimal residual disease, thereby affecting clinical outcome [21]. This evidence concerns the gene CD34 and acute myeloid leukemia.